Nurix Therapeutics, Inc. (NRIX): Free Cash Flow
-$263.47M
Year ended 2025-11-30
-$304.53M
Trailing 12 months to 2026-05-31
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-11-30 | -$263.47M | n/m | 2026-01-28, From 2024-12-01 |
| 2024-11-30 | -$181.86M | n/m | 2026-01-28, From 2023-12-01 |
| 2023-11-30 | -$89.77M | n/m | 2026-01-28, From 2022-12-01 |
| 2022-11-30 | -$172.05M | n/m | 2025-01-28, From 2021-12-01 |
| 2021-11-30 | -$90.03M | n/m | 2023-02-09, From 2020-12-01 |
| 2020-11-30 | -$4.63M | n/m | 2022-01-28, From 2019-12-01 |
| 2019-11-30 | -$1.05M | n/a | 2022-01-28, From 2018-12-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | -$263.47M | n/m |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | -$171.21M | n/m |
| Standard Biotools Inc. (LAB) | 2025-12-31 | -$82.65M | n/m |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | -$74.50M | n/m |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | -$141.44M | n/m |
| Cytokinetics Inc (CYTK) | 2025-12-31 | -$534.82M | n/m |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $10.19M | +980.7% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | -$75.81M | n/m |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | -$174.07M | n/m |
Compare NRIX, SPRY, LAB, ARCT side by side · Screen every company in Pharmaceutical Preparations ↗